GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
P

PharmaCorp Rx PCRX.V · CAD

N/A · TSX Venture · 🇨🇦 Canada

Compare

0.40

0.00%

Close of 9 Nov 2026, in CAD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CAD, from our data supplier.

FY2025

Revenue

C$20.9m

FY2021FY2025

Net income

−C$1.4m

FY2021FY2025

Free cash flow

−C$171,235

FY2021FY2025

Shareholders' equity

C$51.9m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueC$20.9mC$5.8m———
Gross profitC$8.3mC$2.2m———
Operating income−C$1.2m−C$1.6m−C$577,960−C$563,177−C$26,500
Net income−C$1.4m−C$1.1m−C$470,428−C$517,085−C$25,800
Diluted earnings per share-0.01-0.01-0.00-0.00-0.00

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsC$65.6mC$35.2mC$2.3mC$2.7mC$1.0m
Total liabilitiesC$13.3mC$4.6mC$46,185C$16,465C$26,343
DebtC$3.1mC$318,206———
Shareholders' equityC$51.9mC$30.3mC$2.3mC$2.7mC$974,182
Shares outstanding117m117m117m117m40m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsC$2.0mC$124,968−C$519,458−C$120,183C$500
Capital spending−C$2.2m−C$6,890———
Free cash flow−C$171,235C$118,078−C$519,458−C$120,183C$500

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueC$7.7mC$7.1mC$7.6mC$4.8mC$4.4mC$4.0mC$4.4mC$1.1m
Gross profitC$3.1mC$2.8mC$3.0mC$2.0mC$1.7mC$1.6mC$1.7mC$415,424
Operating income−C$119,563−C$51,285−C$636,361−C$498,816−C$330,681C$228,166C$358,167−C$1.1m
Net incomeC$30,257C$108,202−C$852,383−C$427,516−C$384,070C$241,913C$721,210−C$975,861
Diluted earnings per share0.000.00-0.01-0.00-0.000.000.01-0.01
Cash from operations—−C$2.0mC$1.0m———C$1.0m—
Capital spending——−C$2.0m—−C$2.0m———
Free cash flow——−C$1.0m—————
Total assetsC$64.3mC$63.1mC$65.6mC$39.7mC$35.4mC$35.4mC$35.2mC$32.1m
DebtC$3.1mC$3.1mC$3.1mC$3.1mC$280,500C$299,353C$318,206C$337,059
Shareholders' equityC$52.8mC$52.4mC$51.9mC$30.0mC$30.2mC$30.6mC$30.3mC$29.8m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income30.0%——
Net income40.1%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin39.3%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022
Price to earnings-37.5-60.3-52.4-46.0
Price to sales2.510.9——

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.